Explore more publications!
Massachusetts Healthcare Journal
Submit Press Release

Massachusetts Healthcare Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Healthcare Journal.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on October 24, 2025

zakipoint Health and ProNexus Advisory Partner to Empower Self-Funded Employers with CFO-Level Healthcare Cost Control
October 24, 2025

zakipoint Health and ProNexus Advisory Partner to Empower Self-Funded Employers with CFO-Level Healthcare Cost Control

Indeterminate EIN Presswire
Northeast Health Services Expands Access to Mental Health Care with New Clinics in Brighton and Watertown
October 24, 2025

Northeast Health Services Expands Access to Mental Health Care with New Clinics in Brighton and Watertown

Indeterminate EIN Presswire
Surgery Partners, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call Details
October 24, 2025

Surgery Partners, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call Details

Indeterminate GlobeNewswire
Pennant Announces Third Quarter 2025 Earnings Release and Call
October 24, 2025

Pennant Announces Third Quarter 2025 Earnings Release and Call

Indeterminate GlobeNewswire
Enzon and Viskase Announce Amendment to Merger Agreement
October 24, 2025

Enzon and Viskase Announce Amendment to Merger Agreement

Indeterminate GlobeNewswire
60 Iconic Canadian Landmarks to Light Up Blue for World Occupational Therapy Day
October 24, 2025

60 Iconic Canadian Landmarks to Light Up Blue for World Occupational Therapy Day

Indeterminate GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 24, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
October 24, 2025

Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

Indeterminate GlobeNewswire
Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences
October 24, 2025

Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

Indeterminate GlobeNewswire
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
October 24, 2025

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

Indeterminate GlobeNewswire
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 24, 2025

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Indeterminate GlobeNewswire
Picard Issues Statement on Intraday Stock Price
October 24, 2025

Picard Issues Statement on Intraday Stock Price

Indeterminate GlobeNewswire
Theriva Biologics Provides Response to Unusual Market Action
October 24, 2025

Theriva Biologics Provides Response to Unusual Market Action

Indeterminate GlobeNewswire
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
October 24, 2025

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Indeterminate GlobeNewswire
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
October 24, 2025

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Indeterminate GlobeNewswire
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 24, 2025

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Indeterminate GlobeNewswire
BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 24, 2025

BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Indeterminate GlobeNewswire
Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference
October 24, 2025

Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference

Indeterminate GlobeNewswire
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors
October 24, 2025

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors

Indeterminate GlobeNewswire
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
October 24, 2025

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions